Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
Spruce Biosciences (NASDAQ:SPRB) was downgraded by analysts at
Wall Stre
Spruce Biosciences (NASDAQ:SPRB) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Spruce Biosciences (NASDAQ:SPRB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $220.00 price target on the stock.
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors [Yahoo! Finance]